A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Public ClinicalTrials.gov record NCT06774963. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Open-label, Dose Escalation and Dose Expansion Study for LNCB74, a B7-H4 Targeted Antibody Drug Conjugate, as Monotherapy in Participants With Advanced Solid Tumors
Study identification
- NCT ID
- NCT06774963
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- NextCure, Inc.
- Industry
- Enrollment
- 145 participants
Conditions and interventions
Conditions
Interventions
- LNCB74 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 6, 2025
- Primary completion
- Nov 30, 2026
- Completion
- Nov 30, 2026
- Last update posted
- Dec 15, 2025
2025 – 2026
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Hoag Family Cancer Institute | Newport Beach | California | 92663 | Recruiting |
| St. Elizabeth Healthcare | Edgewood | Kentucky | 41017 | Recruiting |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | Recruiting |
| Washington University, Siteman Cancer Center | St Louis | Missouri | 63108 | Recruiting |
| John Theurer Cancer Ctr at Hackensack Univ. Med Ctr. | Hackensack | New Jersey | 07601 | Not yet recruiting |
| Roswell Park Comprehensive Cancer Center | Buffalo | New York | 14203 | Recruiting |
| Cleveland Clinic Taussig Cancer Institute | Cleveland | Ohio | 44195 | Recruiting |
| Sidney Kimmel Comprehensive Center at Jefferson | Philadelphia | Pennsylvania | 19107 | Recruiting |
| UPMC | Pittsburgh | Pennsylvania | 15213 | Recruiting |
| MD Anderson | Houston | Texas | 77030 | Recruiting |
| NEXT Oncology | San Antonio | Texas | 78229 | Completed |
| UT Health San Antonio - MD Anderson Cancer Center | San Antonio | Texas | 78229 | Recruiting |
| Intermountain/LDS Hospital Ph 1 Research Program | Salt Lake City | Utah | 84143 | Recruiting |
| Inova Schar Cancer Institute | Falls Church | Virginia | 22031 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06774963, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 15, 2025 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06774963 live on ClinicalTrials.gov.